>중동 및 아프리카 바이러스 벡터 정제 시장, 제품 및 서비스별(제품 및 서비스), 유형(레트로바이러스 벡터, 백신 바이러스, 아데노바이러스 벡터, 아데노 관련 바이러스 벡터, 렌티바이러스 및 기타), 워크플로(상류 처리 및 하류 처리), 정제 기술(밀도 구배 초원심분리, 초여과, 침전, 2상 추출 시스템 및 크로마토그래피), 운영 규모(전임상/임상 및 상업적), 전달 방법(체내 및 체외), 질병 지표(암, 유전적 질환, 감염성 질환 , 수의학적 질병 및 기타), 응용 분야(안티센스 및 RNAi, 유전자 치료, 세포 치료 및 백신학), 최종 사용자(생명공학 회사, 제약 회사, 계약 연구 기관, 계약 개발 및 제조 기관(CDMO) 및 학술/연구 기관), 국가(사우디 아라비아, 남아프리카, UAE, 이스라엘, 이집트 및 중동 및 아프리카의 나머지 지역) 산업 동향 및 예측 2028
시장 분석 및 통찰력: 중동 및 아프리카 바이러스 벡터 정화 시장
바이러스 벡터 정제 시장은 2021년에서 2028년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년에서 2028년의 예측 기간 동안 12.4%의 CAGR로 성장하고 있으며 2028년까지 2,217만 달러에 도달할 것으로 예상된다고 분석합니다. 바이러스 벡터에 대한 수요 증가는 바이러스 벡터 정제 시장의 원동력으로 작용하고 있습니다.
분자 생물학자들은 종종 바이러스 벡터를 사용하여 유전 물질을 세포로 전달합니다. 이 절차는 생체 내(살아있는 유기체 내부) 또는 세포 배양(시험관 내)에서 수행될 수 있습니다. 바이러스는 감염된 세포 내부로 유전체를 효율적으로 운반하기 위해 특수한 분자 메커니즘을 개발했습니다. 형질 도입은 벡터에 의한 유전자 또는 기타 유전 물질의 전달이며 감염된 세포는 형질 도입된 것으로 불립니다.
COVID-19의 출현과 바이러스 백신에 대한 수요는 바이러스 벡터 정제 시장을 활성화하고 있습니다. 확장성 부족은 바이러스 벡터 정제 시장에 제약이 됩니다. 감염성 질병의 증가는 바이러스 벡터 정제 시장에 기회로 작용합니다. 숙련된 인력의 부족은 바이러스 벡터 정제 시장에 대한 과제입니다.
바이러스 벡터 정제 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 바이러스 벡터 정제 시장 시나리오를 이해하려면 Data Bridge Market Research에 연락하여 분석가 브리핑을 요청하세요. 당사 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다.
바이러스 벡터 정제 시장 범위 및 시장 규모
The viral vector purification market is categorized into nine notable segments which are based on the product & services, type, workflow, purification technique, scale of operation, delivery method, disease indication, application and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product & services, the viral vector purification market is segmented into products and services. In 2021, products segment is expected to dominate the viral vector purification market due to availability of diverse range of innovative solutions for vector purification.
- On the basis of type, the viral vector purification market is segmented into retroviral vectors, vaccine virus, adenoviral vectors, adeno-associated viral vectors, lentivirus and other. In 2021, adeno-associated viral vectors segment is expected to dominate the viral vector purification market due to broad range of infectivity of AAV.
- On the basis of workflow, the viral vector purification market is segmented into upstream processing and downstream processing. In 2021, upstream processing segment is expected to dominate the viral vector purification market because the viral vectors produced using this process can be harvested from cells in a short window of time post transfection.
- On the basis of purification technique, the viral vector purification market is segmented into density-gradient ultracentrifugation, ultrafiltration, precipitation, two-phase extraction systems and chromatography. In 2021, chromatography segment is expected to dominate the viral vector purification market because it has been widely used for purification of vaccines and gene therapy vectors.
- On the basis of scale of operation, the viral vector purification market is segmented into preclinical / clinical and commercial. In 2021, preclinical / clinical segment is expected to dominate the viral vector purification market due to rising investment for research and development activities by major healthcare organizations.
- On the basis of delivery method, the viral vector purification market is segmented into in vivo and ex vivo. In 2021, in vivo segment is expected to dominate the viral vector purification market due to its high availability and process reliability.
- On the basis of disease indication, the viral vector purification market is segmented into cancer, genetic disorders, infectious diseases, veterinary disease and other. In 2021, genetic disorders segment is expected to dominate the viral vector purification market owing to the rising incidence and prevalence of genetic disorders.
- 응용 프로그램을 기준으로, 바이러스 벡터 정제 시장은 안티센스 및 RNAi, 유전자 치료, 세포 치료 및 백신학으로 세분화됩니다. 2021년에는 유전자 치료 부문이 의료 분야의 광범위한 응용 분야로 인해 바이러스 벡터 정제 시장을 지배할 것으로 예상됩니다.
- 최종 사용자를 기준으로, 바이러스 벡터 정제 시장은 생명공학 회사, 제약 회사, 계약 연구 기관, 계약 개발 및 제조 기관(CDMO) 및 학술/연구 기관으로 세분화됩니다. 2021년에는 학술/연구 기관 부문이 다양한 의료 기관과 정부 기관의 연구 노력을 장려하기 위한 이니셔티브 활동이 증가함에 따라 바이러스 벡터 정제 시장을 지배할 것으로 예상됩니다.
중동 및 아프리카 바이러스 벡터 정화 시장 국가 수준 분석
중동 및 아프리카 바이러스 벡터 정제 시장을 분석하고, 위에 언급된 대로 국가, 제품 및 서비스, 유형, 워크플로, 정제 기술, 운영 규모, 전달 방법, 질병 지표, 응용 분야 및 최종 사용자별로 시장 규모 정보를 제공합니다.
중동 및 아프리카 바이러스 벡터 정제 시장 보고서에서 다루는 국가는 사우디아라비아, 남아프리카공화국, UAE, 이스라엘, 이집트 및 기타 중동 및 아프리카 국가입니다.
중동 및 아프리카는 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다. 중동 및 아프리카 국가에서는 인구가 빠르게 증가하고 의료비가 증가함에 따라 바이러스 벡터 정제에 대한 수요가 매우 빠르게 증가하고 있습니다. 사우디 아라비아는 중동 및 아프리카 바이러스 벡터 정제 시장을 주도할 것으로 예상됩니다. 사우디 아라비아는 중동 및 아프리카에서 치료를 위해 고급 바이러스 벡터 정제 제품을 활용하는 주요 국가 중 하나이기 때문입니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 중동 및 아프리카 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
제조업체의 전략적 이니셔티브는 바이러스 벡터 정제 시장의 플레이어에게 새로운 기회를 창출합니다.
바이러스 벡터 정제 시장은 또한 모든 국가 성장에 대한 자세한 시장 분석을 제공합니다. 게다가, 중동 및 아프리카 지역의 바이러스 벡터 정제 시장 참여자들 간의 바이러스 벡터 정제 판매, 파트너십, 인수, 유통 계약의 성장에 대한 자세한 데이터를 제공합니다. 이 데이터는 2011년부터 2019년까지의 과거 기간에 대한 것입니다.
경쟁 환경 및 바이러스 벡터 정화 시장 점유율 분석
바이러스 벡터 정제 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선입니다. 위에 제공된 데이터 포인트는 중동 및 아프리카 바이러스 벡터 정제 시장과 관련된 회사의 초점에만 관련이 있습니다.
중동 및 아프리카 바이러스 벡터 정제 시장 보고서에서 다루는 주요 업체는 Applied Biological Materials Inc., Creative Biolabs, Bio-Rad Laboratories, Inc., Merck KGaA, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., uniQure NV, BioVision Inc. 등 국내 업체입니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.
또한 전 세계 여러 회사에서 많은 계약과 협정을 체결하면서 바이러스 벡터 정제 시장도 가속화되고 있습니다.
예를 들어,
- 2021년 1월, Thermo Fisher Scientific Inc.는 벨기에의 Novsep의 바이러스 벡터 제조 사업 인수를 완료했다고 발표했습니다. 이를 통해 회사는 시장을 더욱 다각화할 수 있게 되었습니다.
시장 참여자들의 협력, 합작투자 및 기타 전략은 바이러스 벡터 정제 시장에서 회사의 인상을 강화하고 있으며, 이는 또한 조직의 매출 성장을 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET APPLICATION COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 MARKET OVERVIEW
4.1 DRIVERS
4.1.1 RISING DEMAND FOR VIRAL VECTORS
4.1.2 AVAILABILITY OF DIVERSE RANGE OF INNOVATIVE SOLUTIONS FOR VECTOR PURIFICATION
4.1.3 EMERGENCE OF COVID-19 AND DEMAND FOR VACCINE DEVELOPMENT
4.1.4 BENEFITS OF VIRAL VECTORS FOR GENE THERAPY
4.1.5 GROWING USAGE OF AAV VECTORS FOR DELIVERY OF SIRNA IN MAMMALIAN CELLS
4.2 RESTRAINTS
4.2.1 LACK OF SCALABILITY
4.2.2 LIMITATIONS OF DOWNSTREAM PURIFICATION
4.3 OPPORTUNITIES
4.3.1 GROWING CANCER BURDEN WORLDWIDE
4.3.2 RISING NUMBER OF INFECTIOUS DISEASES
4.3.3 GROWING GERIATRIC POPULATION
4.3.4 RISING HEALTH CONSCIOUSNESS AND INCREASING SPENDING ON HEALTHCARE
4.4 CHALLENGES
4.4.1 BIOLOGICAL CHALLENGES
4.4.2 SHORTAGE OF SKILLED PERSONNEL
5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: REGULATIONS
1 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES
1.1 OVERVIEW
1.2 PRODUCTS
1.2.1 RESIN
1.2.2 KIT
1.2.3 REAGENT
1.2.4 PREPACKED COLUMN
1.2.5 CASSETTE
1.2.6 CAPSULE
1.2.7 FILTER PLATE
1.3 SERVICES
2 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE
2.1 OVERVIEW
2.2 CHROMATOGRAPHY
2.2.1 AFFINITY CHROMATOGRAPHY
2.2.2 ION-EXCHANGE CHROMATOGRAPHY
2.2.3 SIZE-EXCLUSION CHROMATOGRAPHY
2.2.4 HYDROPHILIC INTERACTION CHROMATOGRAPHY
2.3 DENSITY-GRADIENT ULTRACENTRIFUGATION
2.4 ULTRAFILTRATION
2.5 PRECIPITATION
2.6 TWO-PHASE EXTRACTION SYSTEMS
3 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY TYPE
3.1 OVERVIEW
3.2 ADENO-ASSOCIATED VIRAL VECTORS
3.3 ADENOVIRAL VECTORS
3.3.1 MASTADENOVIRUS
3.3.2 AVIADENOVIRUS
3.3.3 SIADENOVIRUS
3.3.4 ATADENOVIRUS
3.3.5 ICHTADENOVIRUS
3.4 LENTIVIRUS
3.5 RETROVIRAL VECTORS
3.5.1 REPLICATION DEFECTIVE
3.5.2 REPLICATION-COMPETENT
3.6 VACCINE VIRUS
3.7 OTHER
4 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW
4.1 OVERVIEW
4.2 UPSTREAM PROCESSING
4.3 DOWNSTREAM PROCESSING
5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION
5.1 OVERVIEW
5.2 PRECLINICAL / CLINICAL
5.3 COMMERCIAL
6 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY MODE
6.1 OVERVIEW
6.2 IN VIVO
6.3 EX VIVO
7 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION
7.1 OVERVIEW
7.2 GENETIC DISORDERS
7.2.1 THALASSEMIA
7.2.2 CYSTIC FIBROSIS
7.2.3 TAY-SACHS DISEASE
7.2.4 SICKLE CELL ANEMIA
7.2.5 OTHERS
7.3 INFECTIOUS DISEASES
7.3.1 MEASLES VIRUS
7.3.2 VESICULAR STOMATITIS VIRUS
7.3.3 NOVEL ADENOVIRUSES
7.3.4 CYTOMEGALOVIRUS
7.3.5 OTHERS
7.4 VETERINARY DISEASE
7.5 CANCER
7.6 OTHER
8 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 GENE THERAPY
8.2.1 RECOMBINANT PROTEIN EXPRESSION
8.2.2 FUNCTIONAL ASSAYS
8.2.3 PROTEIN CHARACTERIZATION
8.2.4 IN VITRO TRANSCRIPTION
8.2.5 OTHERS
8.3 CELL THERAPY
8.4 VACCINOLOGY
8.5 ANTISENSE & RNAI
9 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY END USER
9.1 OVERVIEW
9.2 ACADEMIC/ RESEARCH INSTITUTES
9.3 PHARMACEUTICAL COMPANIES
9.4 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO)
9.5 BIOTECHNOLOGY COMPANIES
9.6 CONTRACT RESEARCH ORGANIZATIONS
10 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY GEOGRAPHY
10.1 MIDDLE EAST & AFRICA
10.1.1 SOUTH AFRICA
10.1.2 SAUDI ARABIA
10.1.3 UAE
10.1.4 EGYPT
10.1.5 ISRAEL
10.1.6 REST OF MIDDLE EAST & AFRICA
11 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
12 COMPANY PROFILE
12.1 THERMO FISHER SCIENTIFC INC.
12.1.1 COMPANY SNAPSHOT
12.1.2 REVENUE ANALYSIS
12.1.3 COMPANY SHARE ANALYSIS
12.1.4 PRODUCT PORTFOLIO
12.1.5 RECENT DEVELOPMENTS
12.2 CYTIVA (A SUBSIDIARY OF DANAHER)
12.2.1 COMPANY SNAPSHOT
12.2.2 REVENUE ANALYSIS
12.2.3 COMPANY SHARE ANALYSIS
12.2.4 PRODUCT PORTFOLIO
12.2.5 RECENT DEVELOPMENT
12.3 MERCK KGAA
12.3.1 COMPANY SNAPSHOT
12.3.2 REVENUE ANALYSIS
12.3.3 COMPANY SHARE ANALYSIS
12.3.4 PRODUCT PORTFOLIO
12.3.5 RECENT DEVELOPMENT
12.4 AGILENT TECHNOLOGIES, INC.
12.4.1 COMPANY SNAPSHOT
12.4.2 REVENUE ANALYSIS
12.4.3 COMPANY SHARE ANALYSIS
12.4.4 PRODUCT PORTFOLIO
12.4.5 RECENT DEVELOPMENT
12.5 FUJIFILM DIOSYNTH BIOTECHNOLOGIES
12.5.1 COMPANY SNAPSHOT
12.5.2 PRODUCT PORTFOLIO
12.6 ADDGENE
12.6.1 COMPANY SNAPSHOT
12.6.2 PRODUCT PORTFOLIO
12.6.3 RECENT DEVELOPMENT
12.7 ALDEVRON
12.7.1 COMPANY SNAPSHOT
12.7.2 PRODUCT PORTFOLIO
12.7.3 RECENT DEVELOPMENTS
12.8 APPLIED BIOLOGICAL MATERIALS INC.
12.8.1 COMPANY SNAPSHOT
12.8.2 PRODUCT PORTFOLIO
12.8.3 RECENT DEVELOPMENT
12.9 BIA SEPARATIONS
12.9.1 COMPANY SNAPSHOT
12.9.2 PRODUCT PORTFOLIO
12.9.3 RECENT DEVELOPMENTS
12.1 BIO-RAD LABORATORIES, INC.
12.10.1 COMPANY SNAPSHOT
12.10.2 REVENUE ANALYSIS
12.10.3 PRODUCT PORTFOLIO
12.10.4 RECENT DEVELOPMENT
12.11 BIOVISION INC.
12.11.1 COMPANY SNAPSHOT
12.11.2 PRODUCT PORTFOLIO
12.11.3 RECENT DEVELOPMENT
12.12 BATAVIA BIOSCIENCES B.V.
12.12.1 COMPANY SNAPSHOT
12.12.2 PRODUCT PORTFOLIO
12.12.3 RECENT DEVELOPMENT
12.13 CREATIVE BIOGENE
12.13.1 COMPANY SNAPSHOT
12.13.2 PRODUCT PORTFOLIO
12.13.3 RECENT DEVELOPMENTS
12.14 CREATIVE BIOLABS
12.14.1 COMPANY SNAPSHOT
12.14.2 SERVICE PORTFOLIO
12.15 IDT BIOLOGIKA GMBH
12.15.1 COMPANY SNAPSHOT
12.15.2 PRODUCT PORTFOLIO
12.15.3 RECENT DEVELOPMENTS
12.16 PROBIOGEN AG
12.16.1 COMPANY SNAPSHOT
12.16.2 PRODUCT PORTFOLIO
12.16.3 RECENT DEVELOPMENTS
12.17 SIRION-BIOTECH GMBH
12.17.1 COMPANY SNAPSHOT
12.17.2 PRODUCT PORTFOLIO
12.17.3 RECENT DEVELOPMENTS
12.18 TAKARA BIO INC.
12.18.1 COMPANY SNAPSHOT
12.18.2 REVENUE ANALYSIS
12.18.3 PRODUCT PORTFOLIO
12.18.4 RECENT DEVELOPMENTS
12.19 UNIQURE N.V.
12.19.1 COMPANY SNAPSHOT
12.19.2 REVENUE ANALYSIS
12.19.3 PRODUCT PORTFOLIO
12.19.4 RECENT DEVELOPMENT
12.2 WAISMAN BIOMANUFACTURING
12.20.1 COMPANY SNAPSHOT
12.20.2 PRODUCT PORTFOLIO
12.20.3 RECENT DEVELOPMENTS
13 QUESTIONNAIRE
14 RELATED REPORTS
표 목록
LIST OF TABLES
TABLE 1 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA SERVICES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA DENSITY-GRADIENT ULTRACENTRIFUGATION IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA ULTRAFILTRATION IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA PRECIPITATION IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA TWO-PHASE EXTRACTION SYSTEMS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA ADENO-ASSOCIATED VIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA LENTIVIRUS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA VACCINE VIRUS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA OTHER IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA UPSTREAM PROCESSING IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA DOWNSTREAM PROCESSING IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA PRECLINICAL / CLINICAL IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA COMMERCIAL IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY MODE, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA IN VIVO IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA EX VIVO IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA VETERINARY DISEASE IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA CANCER IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA OTHER IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA CELL THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA VACCINOLOGY IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA ANTISENSE & RNAI IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA ACADEMIC/ RESEARCH INSTITUTES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA PHARMACEUTICAL COMPANIES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA BIOTECHNOLOGY COMPANIES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA CONTRACT RESEARCH ORGANIZATIONS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 64 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 65 MIDDLE EAST & AFRICA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 66 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)
TABLE 71 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 SOUTH AFRICA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 73 SOUTH AFRICA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 74 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 75 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)
TABLE 76 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 77 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 78 SOUTH AFRICA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 79 SOUTH AFRICA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 80 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 81 SOUTH AFRICA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 82 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 85 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)
TABLE 86 SAUDI ARABIA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)
TABLE 87 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 SAUDI ARABIA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 SAUDI ARABIA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 91 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)
TABLE 92 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 93 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 94 SAUDI ARABIA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 95 SAUDI ARABIA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 96 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 97 SAUDI ARABIA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 98 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 UAE VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 100 UAE PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 101 UAE VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)
TABLE 102 UAE CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)
TABLE 103 UAE VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 104 UAE RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 UAE ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 106 UAE VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 107 UAE VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)
TABLE 108 UAE VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 109 UAE VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 110 UAE GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 111 UAE INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 112 UAE VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 113 UAE GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 114 UAE VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 115 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 116 EGYPT PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 117 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)
TABLE 118 EGYPT CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)
TABLE 119 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 120 EGYPT RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 121 EGYPT ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 123 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)
TABLE 124 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 125 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 126 EGYPT GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 127 EGYPT INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 128 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 129 EGYPT GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 130 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 131 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 132 ISRAEL PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 133 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)
TABLE 134 ISRAEL CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)
TABLE 135 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 136 ISRAEL RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 137 ISRAEL ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 139 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)
TABLE 140 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 141 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 142 ISRAEL GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 143 ISRAEL INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 144 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 145 ISRAEL GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 146 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 147 REST OF MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
그림 목록
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 11 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: SEGMENTATION
FIGURE 12 AVAILABILITY OF DIVERSE RANGE OF INNOVATIVE SOLUTIONS FOR VECTOR PURIFICATION IS DRIVING THE MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 PRODUCTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET
FIGURE 15 ESTIMATED NUMBER OF NEW CASES IN MALE AND FEMALE (ALL AGE GROUP) WORLDWIDE IN 2018
FIGURE 1 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PRODUCT & SERVICES, 2020
FIGURE 2 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PRODUCT & SERVICES, 2021-2028 (USD MILLION)
FIGURE 3 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PRODUCT & SERVICES, CAGR (2021-2028)
FIGURE 4 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE
FIGURE 5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PURIFICATION TECHNIQUE, 2020
FIGURE 6 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PURIFICATION TECHNIQUE, 2021-2028 (USD MILLION)
FIGURE 7 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PURIFICATION TECHNIQUE, CAGR (2021-2028)
FIGURE 8 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PURIFICATION TECHNIQUE, LIFELINE CURVE
FIGURE 9 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE, 2020
FIGURE 10 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE, 2021-2028 (USD MILLION)
FIGURE 11 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 12 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 13 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY WORKFLOW, 2020
FIGURE 14 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY WORKFLOW, 2021-2028 (USD MILLION)
FIGURE 15 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY WORKFLOW, CAGR (2021-2028)
FIGURE 16 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY WORKFLOW, LIFELINE CURVE
FIGURE 17 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY SCALE OF OPERATION, 2020
FIGURE 18 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
FIGURE 19 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY SCALE OF OPERATION, CAGR (2021-2028)
FIGURE 20 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY SCALE OF OPERATION, LIFELINE CURVE
FIGURE 21 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DELIVERY MODE, 2020
FIGURE 22 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DELIVERY MODE, 2021-2028 (USD MILLION)
FIGURE 23 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DELIVERY MODE, CAGR (2021-2028)
FIGURE 24 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DELIVERY MODE, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DISEASE INDICATION, 2020
FIGURE 26 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DISEASE INDICATION, 2021-2028 (USD MILLION)
FIGURE 27 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DISEASE INDICATION, CAGR (2021-2028)
FIGURE 28 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DISEASE INDICATION, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY APPLICATION, 2020
FIGURE 30 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 31 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 32 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 33 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY END USER, 2020
FIGURE 34 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 35 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY END USER, CAGR (2021-2028)
FIGURE 36 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: SNAPSHOT (2020)
FIGURE 38 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: BY COUNTRY (2020)
FIGURE 39 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: BY COUNTRY (2021 & 2028)
FIGURE 40 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: BY COUNTRY (2020 & 2028)
FIGURE 41 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE (2021-2028)
FIGURE 42 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
